Helsinn publishes PROVe MF-CTCL study providing new data for mechlorethamine gel use in a real-world setting
March 18, 2021 08:30 ET
|
Helsinn Healthcare S.A.
Helsinn publishes PROVe MF-CTCL study providing new data for mechlorethamine gel use in a real-world setting Lugano, Switzerland, March 18, 2021 – Helsinn, a Swiss pharmaceutical group focused on...